Aurora Cannabis sees FY26 adjusted EBITDA C$52M-C$57M, up 5%-10%

Sees FY26 annual global medical cannabis net revenue up $269M-$281M, driven primarily by 10%-15% annual growth in the global medical cannabis segment; plant propagation revenue to perform in line with traditional seasonal trends, as 65% to 75% of revenues are normally earned in the first half of a calendar year; adjusted gross margins to be strong as the company benefitted from favorable sales mix due to higher global medical cannabis revenue, along with operational efficiencies in Canadian manufacturing sites.